These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 11743666)
21. Prevention of carcinoma of cervix with human papillomavirus vaccine. Gavarasana S; Kalasapudi RS; Rao TD; Thirumala S Indian J Cancer; 2000; 37(2-3):57-66. PubMed ID: 11876611 [TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Yugawa T; Kiyono T Rev Med Virol; 2009 Mar; 19(2):97-113. PubMed ID: 19156753 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic uterine-cervix cancer vaccines in humans. Gariglio P; Benitez-Bribiesca L; Berumen J; Alcocer JM; Tamez R; Madrid V Arch Med Res; 1998; 29(4):279-84. PubMed ID: 9887543 [TBL] [Abstract][Full Text] [Related]
24. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307 [TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus vaccines. Stanley MA Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690 [TBL] [Abstract][Full Text] [Related]
26. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. Lee DW; Anderson ME; Wu S; Lee JH Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129 [TBL] [Abstract][Full Text] [Related]
27. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Govan VA Ann N Y Acad Sci; 2005 Nov; 1056():328-43. PubMed ID: 16387699 [TBL] [Abstract][Full Text] [Related]
28. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029 [TBL] [Abstract][Full Text] [Related]
29. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice]. Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859 [TBL] [Abstract][Full Text] [Related]
30. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854 [TBL] [Abstract][Full Text] [Related]
31. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118 [TBL] [Abstract][Full Text] [Related]
32. Resistance to apoptosis of HPV 16-infected laryngeal cancer cells is associated with decreased Bak and increased Bcl-2 expression. Du J; Chen GG; Vlantis AC; Chan PK; Tsang RK; van Hasselt CA Cancer Lett; 2004 Mar; 205(1):81-8. PubMed ID: 15036664 [TBL] [Abstract][Full Text] [Related]
33. [What clinicians should know about human papilloma virus vaccines]. Sanclemente G Gac Med Mex; 2003; 139(2):173-83. PubMed ID: 12754956 [TBL] [Abstract][Full Text] [Related]
34. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807 [TBL] [Abstract][Full Text] [Related]
35. [Vaccination against human papillomavirus and against the cellular proliferation that it induces: facts and expectations]. Giannouli C; Burny A; Hallez S J Gynecol Obstet Biol Reprod (Paris); 2000 May; 29(3):258-60. PubMed ID: 10804365 [TBL] [Abstract][Full Text] [Related]
36. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Eiben GL; Velders MP; Schreiber H; Cassetti MC; Pullen JK; Smith LR; Kast WM Cancer Res; 2002 Oct; 62(20):5792-9. PubMed ID: 12384540 [TBL] [Abstract][Full Text] [Related]
37. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. Stern PL J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015 [TBL] [Abstract][Full Text] [Related]
39. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. Vandepapeliere P; Barrasso R; Meijer CJ; Walboomers JM; Wettendorff M; Stanberry LR; Lacey CJ J Infect Dis; 2005 Dec; 192(12):2099-107. PubMed ID: 16288373 [TBL] [Abstract][Full Text] [Related]
40. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]